Rate of and response to dose escalation in patients treated with adalimumab for moderately to severely active ulcerative colitis: Subanalysis of ULTRA 2

Category Primary study
JournalJournal of Crohn's and Colitis
Year 2013
This article has no abstract
Epistemonikos ID: 9621ea2ed9d58c7f7e7077114774b1b7b5fe0711
First added on: Feb 05, 2025